NSC 42834
CAS No. : 195371-52-9
(Synonyms: JAK2 Inhibitor V; Z3)
| Size | Price | Stock |
|---|---|---|
| 5mg | $66 | In-stock |
| 10mg | $99 | In-stock |
| 50mg | $385 | In-stock |
| 100mg | $715 | In-stock |
| 200 mg | Get quote | |
| 500 mg | Get quote | |
| We match the lowest price on market. | ||
We offer a substantial discount on larger orders, please inquire via [email protected]
or Fax: (86)21-58955996
Inquiry for price and availability only. Please place your order via our email or fax.
| Cat. No. : | HY-15480 |
| M.Wt: | 344.45 |
| Formula: | C23H24N2O |
| Purity: | >98 % |
| Solubility: | DMSO : ≥ 100 mg/mL;Ethanol : 100 mg/mL (ultrasonic) |
NSC 42834 (JAK2 Inhibitor V), a novel specific inhibitor of Jak2, inhibits Jak2-V617F and Jak2-WT autophosphorylation in a dose-dependent manner but was not cytotoxic to cells at concentrations that inhibited kinase activity. IC50 & Target:Jak2; Jak2-V617F. In Vitro: NSC 42834 (JAK2 Inhibitor V) selectively inhibited Jak2 kinase function with no effect on Tyk2 or c-Src kinase function. NSC 42834 significantly inhibited proliferation of the Jak2-V617F-expressing, human erythroleukemia cell line, HEL 92.1.7. The NSC 42834-mediated reduction in cell proliferation correlated with reduced Jak2 and STAT3 tyrosine phosphorylation levels as well as marked cell cycle arrest. Finally, NSC 42834 inhibited the growth of hematopoietic progenitor cells isolated from the bone marrow of an essential thrombocythemia patient harboring the Jak2-V617F mutation and a polycythemia vera patient carrying a Jak2-F537I mutation.
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Autem earum hic iste maiores, nam neque rem suscipit. Adipisci consequatur error exercitationem fugit ipsam optio qui, quibusdam repellendus sed vero! Debitis.
Inquiry Information- Product Name:
- NSC 42834
- Cat. No.:
- HY-15480
- Quantity:
Your information is safe with us.